Befejeződött3. fázis
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids)
A legfontosabb adatok
- Ki végzi
- Sanofi
- Hol
- Akron, Boise, Cincinnati, Coral Gables, Hawthorne, Nashville, New York, St Louis és Tulsa (Egyesült Államok)Mind a 9 helyszín megnézéseMég 2 másik országban, 6 helyszínen
- Azonosító
- NCT05526521
- EudraCT 2022-000260-22
- U1111-1266-5669
- Állapot
- Befejeződött
- Fázis
- 3. fázis
- Résztvevők
- 15 fő vett részt
- Kezdés
- 2022. aug. 25.
- Befejezés
- 2025. febr. 3.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Dupilumab
- A regiszteradat frissítve
- 2025. november 25.
Ki vehet részt
- Életkor
- 2 év – 11 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 18 feltétel megnézéseKevesebb
Ki vehet részt
- Participant must be ≥ 2 years to <12 years of age, at the time of signing the informed consent
- Participants who had history of a diagnosis of CSU prior to screening (Visit 1) or symptoms consistent with a diagnosis of CSU for at least 3 months in the Investigator's opinion
- Participants with CSU (characterized by recurrent itchy wheals with or without angioedema for >6 weeks) who remain symptomatic at the time of screening despite regular H1-antihistamine treatment
- Body weight within ≥5 kg to <60 kg
- Participant/parent(s)/caregiver(s)/participant's legally authorized representative, as appropriate, willing and able to comply with study visits and related procedures
Ki nem vehet részt
- Severe concomitant illness(es) that, in the Investigator's judgment, would adversely affect the participant's participation in the study
- Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, or antifungals within 2 weeks before the screening visit or during the screening period
- Participation in prior dupilumab clinical study or have been treated with commercially available dupilumab; The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
- Participants with active tuberculosis (TB) or non-tuberculous mycobacterial infection, or a history of incompletely treated
- Diagnosed with, suspected of, or at high risk of endoparasitic infection
- Active malignancy or history of malignancy within 5 years before the baseline visit
- History of systemic hypersensitivity or anaphylaxis to dupilumab including any excipient
- Participants were excluded from the study if any of the following criteria apply:
- Underlying etiology for chronic urticarias other than CSU
- Presence of skin morbidities other than CSU that may interfere with the assessment of the study outcomes
- Participants with a diagnosis of chronic inducible cold urticaria
- Participants with active AD
- Known or suspected immunodeficiency
Helyszínek itt: Egyesült Államok
Még 2 másik országban, 6 helyszínen
- Childrens Hospital Medical Center of Akron- Site Number : 8400020Akron, Egyesült Államok
- Treasure Valley Medical Research Site Number : 8400019Boise, Egyesült Államok
- Cincinnati Children's Hospital Medical Center - PIN- Site Number : 8400001Cincinnati, Egyesült Államok
- Pediatric Dermatology of Miami Site Number : 8400015Coral Gables, Egyesült Államok
- Boston Childrens Health Physicians Site Number : 8400017Hawthorne, Egyesült Államok
- Monroe Carell Jr. Childrens Hospital at Vanderbilt- Site Number : 8400005Nashville, Egyesült Államok
- Columbia University Irving Medical Center- Site Number : 8400003New York, Egyesült Államok
- Washington University School of Medicine- Site Number : 8400004St Louis, Egyesült Államok
- Vital Prospects Clinical Research Institute, P.C.- Site Number : 8400002Tulsa, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
This was a multicenter, single-arm, 24-week treatment, Phase 3 study. The purpose of this study was to investigate the PK and safety of dupilumab in children diagnosed with CSU who remain symptomatic despite the use of H1-antihistamine treatment. Study details included: Screening: 2 to 4 weeks; The treatment duration was 24 weeks; Follow-up period: 12 weeks; The study duration was 38 to 40 weeks (including screening and follow-up); The number of study visits was 6.
A vizsgálat csoportja
- DupilumabA vizsgált kezelés
Administered subcutaneously (SC) every 4 weeks (Q4W) or every 2 weeks (Q2W) with or without an initial loading dose based on weight and age
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Multi-center, Single-arm Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Male and Female Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU)
- A regiszteradat frissítve
- 2025. november 25.